Laurenz Steiner

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

Journal: European journal of haematology

Published: May 26, 2026

New molecules in the therapy of chronic graft-versus-host disease.

New molecules in the therapy of chronic graft-versus-host disease.

Journal: Current opinion in hematology

Published: August 13, 2025

Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.

Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.

Journal: British journal of haematology

Published: June 17, 2025

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Journal: British journal of haematology

Published: May 07, 2025

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.

Journal: Clinical case reports

Published: April 21, 2025

Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.

Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.

Journal: Leukemia research

Published: February 27, 2025

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level.

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level.

Journal: Blood neoplasia

Published: December 13, 2023

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

Journal: Haematologica

Published: February 09, 2023

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

Journal: Leukemia

Published: October 12, 2022

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Journal: Nature communications

Published: July 15, 2022

Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium.

Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium.

Journal: Stem cell research & therapy

Published: June 03, 2022

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Journal: Annals of hematology

Published: January 31, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026